U.S. Beverage Stock News

NYSE:IDA
NYSE:IDAElectric Utilities

Will Strong 2025 Earnings and New 2026 EPS Guidance Change IDACORP's (IDA) Narrative?

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Syndax’s Third FDA Win Accelerates Shift To Multi Product Revenues

Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo. The company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies. Pivotal clinical trials are in progress that could support label expansions and additional indications. Syndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Flywire Taps Payments Veteran As CTO To Drive AI First Growth

Flywire appointed Patrick Blanc as Chief Technology Officer as part of a leadership realignment focused on AI driven product development. Blanc brings payments technology experience from senior roles at Ingenico, Visa, and PayPal. David King moved into the role of Chief Product Officer and Co President of Global Education to support Flywire's product and sector focus. For investors tracking NasdaqGS:FLYW, this leadership reshuffle comes with the stock recently closing at $12.31 and showing...
NasdaqGS:RJET
NasdaqGS:RJETAirlines

Assessing Republic Airways (RJET) Valuation After Recent Share Price Momentum

Republic Airways Holdings (RJET) has drawn fresh attention after recent trading, with the stock up 1.7% on the day and double digit gains over the past month and the past 3 months. See our latest analysis for Republic Airways Holdings. With the latest share price at $21.73, a 1 day share price return of 1.7% builds on a 7 day gain of 10.0% and a 30 day share price return of 26.3%. The year to date move of 10.8% suggests momentum has picked up recently compared with earlier in the year. If...
NasdaqGS:QRVO
NasdaqGS:QRVOSemiconductor

Is It Too Late To Reassess Qorvo (QRVO) After Its Recent Share Price Rebound?

If you are wondering whether Qorvo at around US$82.90 still offers value or is pricing in too much optimism already, you are not alone. The stock has returned 0.8% over the last 7 days and 6.1% over the last 30 days, while the year to date return sits at a 3.9% decline and the 1 year return is 14.0%. This compares to a 19.3% decline over 3 years and a 51.6% decline over 5 years. Recent coverage of Qorvo has focused on its role within the semiconductor sector and how investor expectations are...
NYSE:PBH
NYSE:PBHPharmaceuticals

Assessing Prestige Consumer Healthcare (PBH) Valuation After Mixed Returns And An 11% Intrinsic Value Discount

Recent Share Performance Snapshot Prestige Consumer Healthcare (PBH) has seen mixed share performance recently, with a 1 day return of roughly a 1.3% decline, a flat result over the past week, and gains over the month and past 3 months. Over longer periods the picture is split, with a 13.2% gain year to date and a 14.9% total return over 3 years, set against an 18.2% total return decline over the past year. See our latest analysis for Prestige Consumer Healthcare. At a share price of $69.30,...
NasdaqGS:ALKT
NasdaqGS:ALKTSoftware

Is Alkami Technology (ALKT) Pricing Look Attractive After A 46% One-Year Share Price Slide

If you are wondering whether Alkami Technology is starting to look interesting at its current share price, this article will walk through what that price actually implies about the company. The stock last closed at US$16.55, with returns of a 2.8% decline over 7 days, a 21.9% decline over 30 days, a 27.1% decline year to date and a 46.4% decline over the past year, while the 3 year return sits at 7.1%. These moves come as investors continue to track company specific developments and the...
NYSE:CPRI
NYSE:CPRILuxury

Is Capri Holdings (CPRI) Blending CFO and COO Roles to Recast Its Transformation Ambitions?

Capri Holdings has appointed Tyler Reddien as Chief Financial Officer and Chief Operating Officer, effective March 30, 2026, with interim CFO Rajal Mehta returning to his prior role as Michael Kors brand CFO. The consolidation of finance and operations leadership under Reddien, who brings experience from The Body Shop, Natura &Co, Hertz, and United Airlines, could influence how Capri pursues performance improvement and transformation across its global portfolio. Next, we’ll examine how...
NasdaqGS:LZ
NasdaqGS:LZProfessional Services

Reassessing LegalZoom (LZ) After A 31% One‑Year Share Price Decline

If you are wondering whether LegalZoom.com’s current share price reflects its true worth, you are not alone. This article focuses on what the numbers say about value. The stock last closed at US$7.03, with a 7 day return of 7.2%, but declines of 20.9% over 30 days, 26.7% year to date, and 30.8% over the past year. These moves have put valuation questions front and center for many investors, who are weighing short term swings against the longer term picture. Evergreen coverage like this aims...
NasdaqGS:AMRX
NasdaqGS:AMRXPharmaceuticals

Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments

Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, highlighting progress across specialty, injectables, biosimilars, and complex generics. The company announced multiple product launches and regulatory approvals, expanding its presence in higher value segments. Management highlighted a promising pipeline, including biosimilars expected to enter the US market. Amneal also emphasized its collaboration with Pfizer on GLP-1 therapies as a key focus area for future...
NasdaqGS:CAI
NasdaqGS:CAIBiotechs

Caris Life Sciences Advances Early Detection And AI Tools As Valuation Lags

Caris Life Sciences (NasdaqGS:CAI) reported an interim readout from its Achieve 1 study for the Caris Detect multi cancer early detection blood test. The interim data show sensitivity and specificity that the company says outperform current methylation based approaches. Caris is adding Whole Transcriptome Sequencing to Caris Detect to deepen molecular resolution in the test. The company also introduced a new AI powered breast cancer signature in its Molecular Tumor Board Report to expand...
NasdaqGS:DAKT
NasdaqGS:DAKTElectronic

Daktronics OCVIBE Deal And Leadership Shift Test Rich Valuation Story

Daktronics (NasdaqGS:DAKT) has agreed to supply an integrated digital display system across the OCVIBE campus, a large mixed-use development project. The company also announced an executive leadership change, with the former Interim President and CEO moving into an advisory role. Both updates relate to Daktronics' positioning in large commercial installations and its ongoing leadership structure. Daktronics focuses on electronic scoreboards, digital signage, and large-format LED video...
NYSE:RS
NYSE:RSMetals and Mining

Reliance Dividend Hike And Buybacks Shape Future Payout Sustainability

Reliance, Inc. (NYSE:RS) raised its quarterly dividend. The company is continuing its long term share buyback program. Both actions reflect management’s current approach to capital allocation and shareholder distributions. Reliance, Inc. (NYSE:RS) operates in the metals service center space, supplying processed metal products to a wide range of end markets. In that kind of business, decisions around dividends and buybacks can matter as much to investors as day to day price moves for steel...
NasdaqGS:VEON
NasdaqGS:VEONWireless Telecom

VEON And Hala Ride Hailing Push Tests Digital Services Profit Potential

VEON and ride hailing operator Hala have signed a Memorandum of Understanding to expand mobility services in frontier markets. The partnership aims to combine Hala's ride hailing capabilities with VEON's digital platforms and local presence. The agreement builds on VEON's existing mobility offerings and Hala's scale in Dubai to broaden VEON's digital ecosystem beyond telecom. NasdaqGS:VEON currently trades at $55.89, with a return of 24.9% over the past year and a very large gain over three...
NasdaqCM:RR
NasdaqCM:RRMachinery

Richtech Robotics (RR) Valuation Check After Recent Weak Trading And Price To Book Comparison

Richtech Robotics: Context for Recent Stock Performance Richtech Robotics (RR) has drawn attention after a recent stretch of weak trading, with the stock showing negative returns over the past week, month, and past 3 months. That price action has investors rechecking the story behind this US robotics player. See our latest analysis for Richtech Robotics. At a share price of $2.49, Richtech Robotics has seen momentum fade recently, with a 1 month share price return of 30.45% and a year to date...
NYSE:DNA
NYSE:DNALife Sciences

A Look At Ginkgo Bioworks (DNA) Valuation As It Pivots To Robotics Labs And Biosecurity Divestiture

Ginkgo Bioworks Holdings (DNA) is back in focus after reporting 2025 results that combined smaller losses and lower cash burn with a clear pivot toward robotics-powered autonomous labs and a planned biosecurity divestiture. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release, biosecurity divestiture plan, and new autonomous lab contracts have coincided with heavy selling, including a 30.48% 1-day share price return decline and a 26.79% 7-day share price return decline...
NasdaqGS:PICS
NasdaqGS:PICSDiversified Financial

Assessing PicS (PICS) Valuation After Recent Share Price Swings

PicS stock moves after recent performance shifts PicS (PICS) has drawn fresh attention after recent trading saw a 3.8% one day decline and an 8.7% gain over the past week, compared with weaker performance over the past month and year to date. See our latest analysis for PicS. With the share price at $17.08, PicS has seen a 3.8% one day share price return decline, a strong 7 day rebound, yet softer 30 day and year to date share price returns. This suggests that momentum has cooled after a...
NYSE:ULS
NYSE:ULSProfessional Services

UL Solutions Raises Dividend While Pursuing Digital And Energy Transition Growth

UL Solutions (NYSE:ULS) announced an 11.5% increase to its quarterly dividend. Management highlighted digitalization, energy transition, and sustainability as key areas connected to recent growth efforts. Executives discussed progress in laboratory expansion, software integration, and restructuring initiatives. UL Solutions operates in testing, inspection, certification, and related software, serving companies that need to meet safety, quality, and regulatory standards. As more products,...
NasdaqGS:SDGR
NasdaqGS:SDGRHealthcare Services

Schrödinger (SDGR) Valuation After 2025 Results And Shift To Hosted Licensing Model

Schrödinger (SDGR) has drawn fresh attention after reporting 2025 results, with total revenue of US$255.87 million, sales of US$56.37 million, and a net loss of US$103.27 million, along with operational changes. See our latest analysis for Schrödinger. The earnings update and shift toward hosted, throughput based licensing arrived after a tough stretch for shareholders, with a 90 day share price return decline of 29.23% and a 1 year total shareholder return decline of 45.94%, suggesting...
NYSE:AXS
NYSE:AXSInsurance

Is AXIS Capital’s Expanded Buyback and Dividends Altering The Investment Case For AXIS Capital Holdings (AXS)?

AXIS Capital Holdings recently declared a quarterly US$0.44 common dividend and a US$34.375 Series E preferred dividend per share, both payable on April 15, 2026 to shareholders of record on March 31, 2026, while also authorizing an additional US$300,000,000 share repurchase program. Together with a board retirement, these capital return moves underline how AXIS is currently prioritizing shareholder distributions alongside its ongoing specialty insurance focus. We’ll now examine how the...
NYSE:SWK
NYSE:SWKMachinery

Stanley Black & Decker (SWK) Is Down 5.9% After Closing Historic New Britain Plant - What's Changed

In late February 2026, Stanley Black & Decker announced it would close its last New Britain, Connecticut manufacturing plant, ending more than 180 years of local production and affecting about 300 workers as demand for single-sided tape measures structurally declines. At the same time, the Board reaffirmed a regular cash dividend of US$0.83 per share, underscoring management’s commitment to ongoing capital returns even as it reshapes its manufacturing footprint. Next, we’ll examine how...
NYSE:HRI
NYSE:HRITrade Distributors

Herc Holdings’ Record Acquisition Puts Integration Progress And Valuation In Focus

Herc Holdings (NYSE:HRI) has completed its largest acquisition to date, expanding its equipment rental footprint across local markets. The company is now concentrating on post-merger integration, including combining operations, systems, and teams across the enlarged network. Management is prioritizing cost synergies, higher used equipment sales, and branch network changes following the closing of the deal. Herc Holdings runs a broad equipment rental business that serves construction,...
NYSE:PMT
NYSE:PMTMortgage REITs

Will Strong Q4 Results and US$2.8 Billion Securitizations Change PennyMac Mortgage Investment Trust's (PMT) Narrative?

PennyMac Mortgage Investment Trust recently reported fourth quarter results, posting earnings per share of US$0.48, an annualized return on common equity of 13%, eight private label securitizations totaling US$2.80 billion, more than US$180 million of retained subordinate bond investments, and issued US$150 million of exchangeable senior notes to bolster liquidity. This combination of earnings strength, expanded securitization activity, and fresh exchangeable debt financing highlights how...
NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook

In February 2026, Supernus Pharmaceuticals reported fourth-quarter 2025 revenue of US$211.57 million and record full-year 2025 revenue of US$718.95 million, but swung to a full-year net loss of US$38.55 million and guided 2026 operating earnings to a range of US$0–US$30 million on expected total revenues of US$840–US$870 million. The results highlighted strong contributions from newer CNS products such as Qelbree, GOCOVRI, ZURZUVAE, and newly approved ONAPGO, alongside the completed Sage...